We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+12.24%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
-$171M
Cap. Flow
-$111M
Cap. Flow %
-7.89%
Top 10 Hldgs %
67.5%
Holding
33
New
7
Increased
5
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71M
2
INSM icon
Insmed
INSM
+$47.7M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$34.8M
4
OMER icon
Omeros
OMER
+$16.7M
5
EPZM
Epizyme, Inc
EPZM
+$16.5M

Top Sells

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$110M
2
AMRN
Amarin Corp
AMRN
+$43.5M
3
UTHR icon
United Therapeutics
UTHR
+$42.5M
4
PCRX icon
Pacira BioSciences
PCRX
+$36.2M
5
VCEL icon
Vericel Corp
VCEL
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$298M
$167M 11.82%
430,691
-118,858
-22% -$43.5M
QURE icon
2
uniQure
QURE
$2.93B
$149M 10.57%
1,911,529
-73,931
-4% -$4.71M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.09B
$144M 10.16%
5,852,836
+4,712,836
+413% +$71M
PCRX icon
4
Pacira BioSciences
PCRX
$1.06B
$122M 8.62%
2,799,916
-852,218
-23% -$36.2M
TVTX icon
5
Travere Therapeutics
TVTX
$5.33B
$76.6M 5.42%
3,812,516
-219,607
-5% -$4.34M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$68.6M 4.86%
17,875,655
– –
UTHR icon
7
United Therapeutics
UTHR
$26.2B
$60.2M 4.26%
770,769
-454,618
-37% -$42.5M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$59.7M 4.23%
4,760,059
+1,281,798
+37% +$16.5M
VCEL icon
9
Vericel Corp
VCEL
$2.43B
$55.4M 3.92%
2,932,152
-1,355,940
-32% -$23.1M
URGN icon
10
UroGen Pharma
URGN
$2B
$51.5M 3.65%
1,433,774
-325,550
-19% -$12M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$312M
$51.1M 3.62%
3,626,545
-631,813
-15% -$10.1M
OMER icon
12
Omeros
OMER
$863M
$47.9M 3.39%
3,051,922
+927,303
+44% +$16.7M
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$44.5M 3.15%
1,506,695
-190,078
-11% -$7.32M
INSM icon
14
Insmed
INSM
$22B
$43.8M 3.1%
+1,711,150
New +$47.7M
KPTI icon
15
Karyopharm Therapeutics
KPTI
$159M
$34.8M 2.46%
386,882
+42,956
+12% +$3.45M
OXFD
16
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$32.2M 2.28%
2,343,524
-265,260
-10% -$4.06M
CORT icon
17
Corcept Therapeutics
CORT
$12.7B
$32.1M 2.27%
2,882,773
-864,680
-23% -$9.63M
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$30.9M 2.19%
+388,470
New +$34.8M
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.93B
$27.8M 1.97%
4,222,558
– –
KDMN
20
DELISTED
Kadmon Holdings, Inc.
KDMN
$24M 1.7%
11,627,900
– –
ADMA icon
21
ADMA Biologics
ADMA
$2.01B
$22.1M 1.56%
5,705,352
+1,117,000
+24% +$4.93M
CCXI
22
DELISTED
ChemoCentryx, Inc.
CCXI
$15.5M 1.1%
1,666,667
– –
STAA icon
23
STAAR Surgical
STAA
$1.21B
$14.2M 1.01%
+484,557
New +$14M
MBIO icon
24
Mustang Bio
MBIO
$4.5M
$12.4M 0.88%
+4,500
New +$12.8M
ANIP icon
25
ANI Pharmaceuticals
ANIP
$1.83B
$11.8M 0.83%
142,943
– –
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Consonance Capital Management held 33 positions worth $1.41B, down 11% from $1.58B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Consonance Capital Management withdrew a net $111M in Q2 2019, closing 3 positions and reducing 12 holdings. Its most notable exit was Myriad Genetics, an estimated $110M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Insmed worth $43.8M.

  • Consonance Capital Management's largest Q2 2019 buy was Insmed: 1,711,150 shares worth $43.8M.
  • Consonance Capital Management added most to Iovance Biotherapeutics in Q2 2019, an estimated $71M increase.
  • Consonance Capital Management's biggest Q2 2019 reduction was Amarin Corp, cutting an estimated $43.5M.
  • Consonance Capital Management fully exited Myriad Genetics in Q2 2019, selling an estimated $110M.
  • Consonance Capital Management's ten largest holdings make up 67% of its $1.41B portfolio in Q2 2019.
  • Consonance Capital Management opened 7 new positions and closed 3 in Q2 2019.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $1.41B.

Based on Consonance Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.